Stage 4 EGFR Mutation Lung Cancer: 74 Real Stories

Stage IV EGFR Non-Small Cell Lung Cancer: Anne's Patient Story

Patient Info: Anne Laporte, Female | Stage IV

Biomarkers: EGFR-mutated; several additional mutations mentioned but not specified

Metastatic Site: Spine; liver; lymph nodes

As of March 2024, Anne was living with Stage IVB EGFR-mutated NSCLC on a clinical trial after progression on Tagrisso, with early signs of decreased tumor burden and major improvement in pain.

The Patient StoryRead more →

Stage IV EGFR Non-Small Cell Lung Cancer: Ashley's Patient Story

Patient Info: Ashley, Female | Stage IV

Biomarkers: EGFR T790M mutation

Metastatic Site: Both lungs / bilateral lung nodules

As of March 2024, Ashley was living with Stage IV EGFR-mutated NSCLC controlled on daily Tagrisso for 43 months, with stable scans but no cancer-free or NED claim.

The Patient StoryRead more →

Stage IV EGFR Lung Cancer: Ivy's Survivor Story

Patient Info: Ivy E., Female, 40s | Stage IV

Biomarkers: EGFR mutation

Metastatic Site: Bone: elbow, cervical spine/neck, rib, pelvis; brain

As of January 2024, Ivy reported no evidence of disease 1 year after right upper lobectomy, after years of response to EGFR-targeted therapy for initially Stage IV lung cancer.

The Patient StoryRead more →

Stage IV EGFR-Mutant Lung Adenocarcinoma Responding to Osimertinib

Patient Info: Anonymized, female, 70+ | Stage IV

Biomarkers: EGFR L833V/H835L mutations; PD-L1 50%; CDK4 amplification; MDM2 amplification

Metastatic Site: contralateral lung, brain

After 3 months of osimertinib, the right upper lobe lesion had decreased and right hilar lymphadenopathy had resolved. The brain lesion remained stable, and subsequent imaging continued to show improvement in the lung lesion.

PubMed CentralRead more →

Lung cancer recurrence in the thyroid, initially mistaken for thyroid cancer

Patient Info: Anonymized, Male | Stage IV

Biomarkers: EGFR exon 19 deletion; TTF-1-positive; Napsin A-positive; PAX8-negative; thyroglobulin staining limited to tumour cells adjacent to normal thyroid tissue

Metastatic Site: thyroid; cervical lymph nodes

After starting osimertinib for EGFR exon 19-deleted recurrent lung adenocarcinoma, he was disease free 5 months after thyroid surgery.

PubMed CentralRead more →

Afatinib-related kidney injury during treatment for EGFR-positive metastatic lung cancer

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: EGFR-positive.

Metastatic Site: pleura

He continued maintenance bevacizumab and atezolizumab after four combination courses for metastatic disease while his renal function remained impaired but stable.

PubMed CentralRead more →

Stage IV EGFR Non-Small Cell Lung Cancer: Tiffany's Patient Story

Patient Info: Tiffany, Female | Stage IV

Biomarkers: EGFR mutation

Metastatic Site: Bone: pelvis, right femur, cervical spine

As of March 2023, Tiffany had benefited from Tagrisso plus Cyramza, but later CT findings suggested worsening disease and she had started a new early-stage clinical trial with results pending.

The Patient StoryRead more →

Stage IV EGFR Lung Adenocarcinoma: Emily's Patient Story

Patient Info: Emily Bannister, Female, 40s | Stage IV

Biomarkers: EGFR Exon 19-positive; no other driver mutations present

Metastatic Site: Intrathoracic lymphatic spread

Emily had Stage IV EGFR Exon 19-positive lung adenocarcinoma with a strong early response to trial-based targeted therapy, and later passed away on March 14, 2023 from complications caused by Stage IV lung cancer.

Lung Cancer Research FoundationRead more →

Living with Cancer & My Survivorship : Lung Cancer

Patient Info: Ashley, Female, Under 40 | Stage IV

Biomarkers: EGFR-positive; T790M mutation

As of September 2021, Ashley was living with incurable but treatable EGFR-positive T790M non-small cell lung cancer and described 43 months on treatment/journey while using community support to sustain hope.

The Patient StoryRead more →

Stage IV EGFR Lung Cancer: Ashley's Patient Story

Patient Info: Ashley, Female | Stage IV

Biomarkers: EGFR-positive; T790M-positive

Metastatic Site: Not reported

As of September 2021, Ashley was living with incurable but treatable EGFR-positive/T790M-positive lung cancer on daily osimertinib/Tagrisso with ongoing oncology monitoring and side-effect management.

The Patient StoryRead more →

Cancer Survivor Story: How I Got Diagnosed with Lung Cancer

Patient Info: Ashley, Female, Under 40 | Stage IV

Biomarkers: EGFR-positive; T790M mutation

Metastatic Site: Both lungs

As of August 2021, Ashley had been living for almost 4 years with incurable but treatable EGFR-positive T790M non-small cell lung cancer involving many tiny nodules across both lungs.

The Patient StoryRead more →

Facial paralysis from progression of EGFR-positive metastatic lung cancer improved with osimertinib

Patient Info: Anonymized, Female, Under 40 | Stage IV

Biomarkers: EGFR exon 21 p.Leu858Arg mutation.

Metastatic Site: brain; leptomeninges and facial nerves

Osimertinib rapidly resolved the bilateral facial weakness and reduced the brain lesions, but after 15 months seizures recurred and three smaller brain metastases had increased in size.

PubMed CentralRead more →

A regressed choroidal metastasis during EGFR-targeted lung cancer treatment

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: EGFR exon 19 deletion.

Metastatic Site: liver; bone; central nervous system; right choroid

The right choroidal metastasis appeared inactive and regressed during systemic treatment, visual acuity remained 20/20, and no local eye treatment was required.

PubMed CentralRead more →

Stage IV EGFR Non-Small Cell Lung Cancer: Saila's Patient Story

Patient Info: Saila Hanninen, Under 40 | Stage IV

Biomarkers: EGFR mutation

After progression on earlier EGFR-directed treatment and other therapies, Saila began chemotherapy and her cancer was stable at the time of the story.

Dana-FarberRead more →

Long response to afatinib in EGFR-mutated lung cancer

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: EGFR L861Q mutation; EGFR G719X mutation

Metastatic Site: multiple bilateral ribs

CT at 30 months showed no recurrence, and he remained well 32 months after starting afatinib.

PubMed CentralRead more →

Stage IV EGFR-mutated lung cancer responding to osimertinib despite new lung opacities

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: EGFR L858R mutation; EGFR T790M mutation

Metastatic Site: bilateral lungs

Over the following year on osimertinib, imaging showed an excellent tumour response with gradual improvement of the lung opacities and sustained clinical improvement.

PubMed CentralRead more →

Osimertinib rechallenge after severe pneumonitis in Stage IV lung cancer

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: EGFR exon 19 deletion; acquired EGFR T790M mutation

Metastatic Site: pleura, liver, bone, leptomeninges

She initially regained a significant response after osimertinib rechallenge without recurrent pneumonitis, but developed progressive leptomeningeal disease after 11 months.

PubMed CentralRead more →

Erlotinib-related uveitis during treatment for stage IV EGFR-mutated lung cancer

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: EGFR L858R mutation-positive.

A partial response to erlotinib was maintained at six months, while the uveitis resolved and did not recur after treatment resumed at a lower dose.

PubMed CentralRead more →

Stage IV EGFR Non-Small Cell Lung Cancer: Ginger's Patient Story

Patient Info: Ginger Tam, Female | Stage IV

Biomarkers: EGFR mutation

Ginger lived for more than 5 years with metastatic lung cancer while receiving multiple research-driven treatments. She died on February 10, 2018.

Delayed Adrenal Insufficiency After Nivolumab for Stage IV Lung Cancer

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: EGFR unmutated; ALK unmutated; ROS1 unmutated

His weakness, fatigue, weight loss, and orthostatic hypotension resolved after hormone replacement, and he returned home independently.

PubMed CentralRead more →

EGFR-Mutated Stage IV Lung Adenocarcinoma With Painful Finger Lesions During Osimertinib

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: EGFR-mutated; EGFR T790M-positive at relapse

She remained on active osimertinib treatment; the finger lesions persisted but were controlled with colloidal oatmeal.

PubMed CentralRead more →

Stage IV EGFR Lung Cancer: Molly's Patient Story

Patient Info: Molly Golbon, Female, Under 40 | Stage IV

Biomarkers: EGFR mutation

Metastatic Site: Left hip; right shoulder; brain

Molly had a strong early response to Tarceva for Stage IV EGFR-mutated lung cancer, with about 50% tumor shrinkage after 2 months and metastatic disease described as almost undetectable; no later remission/NED status is provided in this record.

The Patient StoryRead more →

Metastatic lung cancer causing recurrent small-bowel intussusception

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: EGFR mutation; exon 19 deletion in metastatic bowel lesions

Metastatic Site: small bowel

She recovered satisfactorily after bowel surgery, and care shifted to palliation with long-term nutritional support planned.

PubMed CentralRead more →

Lung Adenocarcinoma Metastatic to the Breast With Inflammatory Breast-Like Symptoms

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: EGFR positive. Breast metastasis: TTF-1 positive

Metastatic Site: right breast

A PET scan after breast radiation showed no metabolically active cancer, but she died 2 months after the breast metastasis was diagnosed.

PubMed CentralRead more →